ArticleClinical, cosmetic and investigational dermatology2026
Correlation Between Improvements in Melasma Quality of Life (MELASQoL-INA) and Modified Melasma Area and Severity Index (mMASI) Following Triple Combination Therapy.
Article in Clinical, cosmetic and investigational dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Melasma is a facial pigmentary disorder that commonly causes psychosocial distress. Quality of life (QoL) is not routinely assessed in daily practice; therefore, its improvement in relation with the reduction of melasma severity remains unclear, especially among people of color. This study aimed to determine whether clinical improvement after triple combination cream (fluocinolone acetonide 0.01%, hydroquinone 4%, and tretinoin 0.05%) correlated with improved QoL. Patients and Methods: Participants with melasma were enrolled in a one-group pretest-posttest study and treated with triple combination cream for 12 weeks. The Melasma Quality of Life Scale (MELASQoL-INA, a validated questionnaire adapted into the Indonesian language) and the modified Melasma Area and Severity Index (mMASI) assessments were carried out at baseline visit and at weeks 4, 8, and 12 to evaluate QoL and clinical severity. Results: Thirty female participants aged 30-60 years, with Fitzpatrick skin type IV or V and without other facial skin conditions, completed the study. The most negatively affected QoL domains were emotional well-being (appearance concerns, embarrassment, and frustration) and social life (desire to interact with other people). Significant improvements were observed in both mMASI (median reduction from 4.45 to 1.80; p < 0.001) and MELASQoL-INA scores (median reduction from 37 to 17; p < 0.001) after 12 weeks of treatment. Although no correlation was observed between mMASI and MELASQoL-INA scores at week 12 (r = 0.029, p = 0.879), a weak positive correlation was found between their respective changes after treatment (r = 0.397, p = 0.03). Conclusion: Clinical improvement in melasma severity following triple combination therapy is modestly associated with improved QoL. However, QoL impairment does not always correspond linearly with disease severity, highlighting the importance of integrating subjective QoL outcomes alongside clinical evaluations in the management of melasma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.